Immunomodulatory drugs as a therapy for multiple myeloma.
Thalidomide and the analogues lenalidomide (CC-5013, Revlimid) and CC-4047 (Actimid) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFalpha and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects. These characteristics have made of them promising drugs for treatment of relapsed, refractory and newly diagnosed MM. It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFalpha and have, except for myelosuppression, less side effects than Thal. Combination of IMiDs with dexamethasone, bortezomib and with chemotherapeutic agents are tested in numerous trials, which will help in determining the optimal combination and administration schedule of different molecules to take advantage of non-overlapping toxicities and synergisms between those agents.
De Raeve
H
H
Department of Pathology, University of Antwerp (UA), Belgium. Hendrik.De.Raeve@uza.be
Vanderkerken
K
K
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology*; D013792:Thalidomide / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016207:Cytokines; D007155:Immunologic Factors; D013792:Thalidomide